RELATIONSHIP BETWEEN O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE (MGMT) PROMOTER METHYLATION STATUS AND TUMOR SIZE ON PREOPERATIVE CONTRAST ENHANCED MRI IN PATIENTS WITH GLIOBLASTOMA MULTIFORME – SINGLE INSTITUTION EXPERIENCE
Date Issued
2018-06-01
Author(s)
Petkovska, Gordana
Bojovska, Valentina
Abstract
Introduction. O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation
status is considered as an important prognostic marker in patients with glioblastoma multiforme.
Patients with methylated MGMT promoter are considered that have better prognosis, have longer
disease free survival and overall survival.
Methods. We performed retrospective analysis of 28 patients with glioblastoma multiforme
intended to be treated with radiotherapy and with known MGMT promoter status. Volume of the
tumor was measured on initial MR of the brain and it was delineated on transversal MR image DICOM
datasets. “Tumor” was defined as contrast enhanced region in T1 weighted image after application of
i.v. contrast.
Results. From 28 patients, 14 patients were with methylated MGMT promotor (MGMT-M) and
14 with wild type MGMT promotor (MGMT-W). Mean MRI tumor volume in MGMT-M group was
45.41 cm3 (range 4.50 cm3 – 95.26 cm3) and in MGMT-W group 50.46 cm3 (range 3.81 cm3 – 134.79
cm3). Comparison of volumes of 2 groups has shown that there are no significant differences between
tumor volumes in the groups p= 0.29864.
Conclusion. In our study we can conclude that there is no correlation between MGMT
methylation status and initial tumor volume in patients with glioblastoma multiforme.
status is considered as an important prognostic marker in patients with glioblastoma multiforme.
Patients with methylated MGMT promoter are considered that have better prognosis, have longer
disease free survival and overall survival.
Methods. We performed retrospective analysis of 28 patients with glioblastoma multiforme
intended to be treated with radiotherapy and with known MGMT promoter status. Volume of the
tumor was measured on initial MR of the brain and it was delineated on transversal MR image DICOM
datasets. “Tumor” was defined as contrast enhanced region in T1 weighted image after application of
i.v. contrast.
Results. From 28 patients, 14 patients were with methylated MGMT promotor (MGMT-M) and
14 with wild type MGMT promotor (MGMT-W). Mean MRI tumor volume in MGMT-M group was
45.41 cm3 (range 4.50 cm3 – 95.26 cm3) and in MGMT-W group 50.46 cm3 (range 3.81 cm3 – 134.79
cm3). Comparison of volumes of 2 groups has shown that there are no significant differences between
tumor volumes in the groups p= 0.29864.
Conclusion. In our study we can conclude that there is no correlation between MGMT
methylation status and initial tumor volume in patients with glioblastoma multiforme.
Subjects
File(s)![Thumbnail Image]()
Loading...
Name
BoA RAD 2018 - str. 357.pdf
Size
5 MB
Format
Adobe PDF
Checksum
(MD5):680ae65dfd1b23d9a5ae237bdfb0c0cc